Palvella Insider Trades: Routine Moves, Not a Stock‑Market Signal
Insider trades at Palvella Therapeutics show routine portfolio moves, not a shift, but the COO’s deep‑discount purchases hint at long‑term conviction amid volatile biotech earnings.
3 minutes to read